Description: CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.
Home Page: www.combigene.com
Agavagen 52A
Lidingö,
181 55
Sweden
Phone:
46 7 04 66 31 63
Officers
| Name | Title |
|---|---|
| Mr. Jan Nilsson | Chief Exec. Officer |
| Associate Prof. David Woldbye | Scientific Founder |
| Prof. Merab Kokaia Ph.D. | Scientific Founder |
| Ms. Louise Aspenberg | Chief Financial Officer |
| Mr. Peter Ekolind | Chief Operating Officer |
| Ms. Karin Agerman | Chief Scientific Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 2.3901 |
| Price-to-Book MRQ: | 1.0621 |
| Price-to-Sales TTM: | 1.6178 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 11 |